Table 1.
Baseline and post-procedural results in patients underwent PEA.
| Variables | PEA (n = 50） |
||
|---|---|---|---|
| Pre | Post | p-value | |
| NYHA (I/II/III/IV), n | 0/13/31/6 | 25/15/9/1 | <0.001 |
| 6MWD, m (n) | 340 ± 118 (32) | 357 ± 135 (29) | 0.50 |
| RAP, mmHg | 7.2 ± 6.6 | 5.4 ± 3.4 | 0.14 |
| sPAP, mmHg | 76.0 ± 17.4 | 37.4 ± 14.3 | <0.001 |
| mPAP, mmHg | 43.0 ± 9.9 | 22.7 ± 7.8 | <0.001 |
| dPAP, mmHg | 24.8 ± 9.0 | 13.8 ± 5.1 | <0.001 |
| PCWP, mmHg | 9.7 ± 5.1 | 9.1 ± 3.6 | 0.86 |
| PVR, Wood units | 11.0 ± 4.7 | 3.8 ± 2.4 | <0.001 |
| PVR, mmHg sec/mL | 0.66 ± 0.28 | 0.23 ± 0.14 | <0.001 |
| Cardiac index, L/min/m2 | 2.0 ± 0.6 | 2.6 ± 0.8 | <0.001 |
| Stroke volume, ml | 44.2 ± 17.3 | 54.8 ± 24.0 | 0.005 |
| Heart rate, /min | 75.1 ± 14.0 | 79.8 ± 14.4 | 0.08 |
| PAC, ml/mmHg | 0.97 ± 0.58 | 2.63 ± 1.55 | <0.001 |
| RC time, sec | 0.54 ± 0.16 | 0.45 ± 0.12 | <0.001 |
| SaO2, % | 91.4 ± 4.5 | 94.9 ± 3.2 | <0.001 |
| SvO2, % | 61.1 ± 9.2 | 66.5 ± 6.4 | <0.001 |
| BNP, pg/ml (n) | 377 ± 431 (43) | 136 ± 151 (41) | 0.001 |
| PH targeted therapy, n (%) | 28 (56) | 16(32) | 0.02 |
| Warfarin, n (%) | 50 (100) | 50 (100) | 1 |
| HOT, n (%) | 19 (38) | 9 (18) | 0.03 |
Values are mean ± standard deviation or n (%) except as noted. 6MWD indicates 6-minute walking distance; BNP, brain natriuretic peptide; dPAP, diastolic pulmonary arterial pressure; HOT, home oxygen therapy; mPAP, mean pulmonary arterial pressure; NYHA, New York Heart Association functional classification; PAC, pulmonary arterial compliance; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SaO2, arterial oxygen saturation; SvO2, mixed venous oxygen saturation; sPAP, systolic pulmonary arterial pressure;